; and (B) in subparagraph (B), by striking annual and inserting biannual . (d) Strategic plan To address infectious diseases (1) Strategic plan (A) In general Not later than 1 year after the date of the enactment of this Act, the Director of the National Institutes of Health (in this section referred to as the Director ), in consultation with the Director of the Biomedical Advanced Research and Development Authority and the Commissioner of Food and Drugs, shall prepare and submit to Congress a strategic plan for fiscal years 2021 through 2030 to identify, treat, and develop vaccines for infectious diseases. Such plan shall take into consideration, the coordinated strategy developed pursuant to section 2802(a) of the Public Health Service Act ( 42 U.S.C. 300hh–1(a) ). (B) Content The plan under subparagraph (A) shall address the following: (i) Research of pathogens, including research on the origins of zoonotic pathogens. (ii) The development of cooperative partnerships to determine treatments and vaccines for COVID–19, and other similar infectious diseases. (iii) A strategy to fund clinical trials to determine which pathogens demonstrate a high mortality rate and high rate of infection. (iv) The development of partnerships with private entities to allow such entities to eliminate industry risk. (2) Expedited approval The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, may designate a treatment or vaccine identified in the plan under this subsection as a breakthrough therapy, a fast track product, or eligible for accelerated approval as appropriate under section 506 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356 ). (3) Authorization of appropriations There are authorized to be appropriated to the Director to carry out this subsection $1,000,000,000 for each fiscal year from 2021 through 2030. (e) Community-Based prevention strategies grant program (1) In general The Secretary of Health and Human Services shall award grants to community-based organizations for